Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials

Vaccine

Volumn 23, Issue 9, 2005, Pages 1170-1177

  Davoudi, Noushin ^a   Tate, Celia A ^b   Warburton, Corinna ^b   Murray, Angus ^b   Mahboudi, Fereidoun ^a   McMaster, W Robert ^b  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b JACK BELL RESEARCH CENTRE   (Canada)

Author keywords

5 Fluorocytosine sensitive; Cytosine deaminase gene; Ganciclovir; Gene targeting; HSV 1 thymidine kinase gene; Leishmania major; Live challenge strain

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; LIVE VACCINE; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME; CONTROLLED STUDY; FEMALE; FUNGAL GENE; GENE TARGETING; HOMOZYGOSITY; LEISHMANIA MAJOR; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMASTIGOTE; RECURRENT DISEASE; SACCHAROMYCES CEREVISIAE;

ANIMALS; CELL SURVIVAL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GANCICLOVIR; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES;

EID: 11144243422     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.08.032     Document Type: Article

References (35)

1. P. Desjeux Leishmaniasis Public health aspects and control Clin. Dermatol. 14 5 1996 417 423
2. P. Moszynski World Health Organisation warns that kala-azar has returned to South Sudan The Lancet 360 2002 1672
3. R. Reithinger, M. Mohsen, K. Aadil, M. Sidiqi, P. Erasmus, and P.G. Coleman Anthroponotic cutaneous leishmaniasis, Kabul Afghanistan Emerg. Infect. Dis. 9 6 2003 727 729
4. P. Desjeux, and J. Alvar Leishmania/HIV co-infections: epidemiology in Europe Ann. Trop. Med. Parasitol. 97 Suppl 1 2003 3 15
5. J.H. Remme, E. Bias, L. Chitsulo, P.M. Desjeux, H.D. Engers, and TP Kanyok Strategic emphases for tropical diseases research: a TDR perspective Trends Parasitol. 18 10 2002 421 426
6. Cox, FEG. Old World leishmaniasis. In: Cox, FEG, editor. The Wellcome Trust Illustrated History of Tropical Diseases. London: The Wellcome Trust; 1996. p. 207-17.
7. A. Nadim, E. Javadian, G. Tahvildar-Bidruni, and M. Ghorbani Effectiveness of leishmanization in the control of cutaneous leishmaniasis Bull. Soc. Pathol. Exot. Filiales 76 4 1983 377 383
8. F. Modabber Experiences with vaccines against cutaneous leishmaniasis: of men and mice Parasitology 98 Suppl S 1989 49 60
9. A.Z. Momeni, and M. Aminjavaheri Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol Eur. J. Dermatol. 13 1 2003 40 43
10. I.M. Gafurov Experience in controlling and preventing zoonotic cutaneous leishmaniasis in Uzbekistan Med. Parazitol. (Mosk) 1 1999 58 59
11. D. Sacks, and N. Noben-Trauth The immunology of susceptibility and resistance to Leishmania major in mice Nat. Rev. Immunol. 2 2002 845 858
12. I. Sharifi, A.R. FeKri, M.R. Aflatonian, A. Khamesipour, A. Nadim, and M.R. Mousavi Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran Lancet 351 9115 1998 1540 1543
13. A.Z. Momeni, T. Jalayer, M. Emamjomeh, A. Khamesipour, F. Zicker, and R.L. Ghassemi A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran Vaccine 17 5 1999 466 472
14. E.A. Khalil, A.M. El Hassan, E.E. Zijlstra, M.M. Mukhtar, H.W. Ghalib, and B. Musa Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan Lancet 356 9241 2000 1565 1569
15. B. Genton, F. Al-Yaman, I. Betuela, R.F. Anders, A. Saul, and K. Baea Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSPl, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children Vaccine 22 1 2003 30 41
16. R.B. Belshe, and W.C. Gruber Safety efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children Philos. Trans. R. Soc. Lond. B Biol. Sci. 356 1416 2001 1947 1951
17. J.J. Treanor, K. Kotloff, R.F. Betts, R. Belshe, F. Newman, and D. Iacuzio Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses Vaccine 18 9-10 1999 899 906
18. A. Cruz, C.M. Coburn, and S.M. Beverley Double targeted gene replacement for creating mutant 88 16 1991 7170 7174
19. J.R. Webb, and W.R. McMaster Leishmania major HEXBP deletion mutants generated by double targeted gene replacement Mol. Biochem. Parasitol. 63 2 1994 231 242
20. P.B. Joshi, D.L. Sacks, G. Modi, and W.R. McMaster Targeted gene deletion of Leishmania major genes encoding developmental stage-specific leishmanolysin (GP63) Mol. Microbiol. 27 3 1998 519 530
21. P.B. Joshi, B.L. Kelly, S. Kamhawi, D.L. Sacks, and W.R. McMaster Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor Mol. Biochem. Parasitol. 120 1 2002 33 40
22. T.W. Spithill, and N. Samaras Genomic organization, chromosomal location and transcription of dispersed and repeated tubulin genes in Leishmania major Mol. Bioc. Parasit. 24 1987 23
23. M.E. Black, T.G. Newcomb, H.M. Wilson, and L.A. Loeb Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy Proc. Natl. Acad. Sci. U.S.A. 93 8 1996 3525
24. P. Erbs, F. Exinger, and R. Jund Characterization of the Saccharomyces cerevisiae FCY1 gene encoding cytosine deaminase and its homologue FCA1 of Candida albicans Curr. Genet. 31 1 1997 1 6
25. J. Mikus, and D. Steverding A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue Parasitol. Int. 48 3 2000 265 269
26. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 22 1984 27 55
27. J.H. LeBowitz, A. Cruz, and S.M. Beverley Thymidine kinase as a negative selectable marker in Leishmania major Mol. Biochem. Parasitol. 51 1992 321 325
28. A. Muyombwe, M. Olivier, M. Ouellette, and B. Papadopoulou Selective killing of Leishmania amastigotes expressing a thymidine kinase suicide gene Exp. Parasitol. 85 1 1997 35 42
29. F.J. Gueiros-Filho, and S.M. Beverley Selection against the dihydrofolate reductase-thymidylate synthase (DHFR-TS) locus as a probe of genetic alterations in Leishmania major Mol. Cell Biol. 16 10 1996 5655 5663
30. M.E. Black Review: enzyme and pathway engineering for suicide gene therapy Genet. Eng. 23 2001 113 127
31. I.M. Germano, J. Fable, S.H. Gultekin, and A. Silvers Adenovirus/herpes simplex-thymidine kinase/GCV complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas J. Neurooncol. 65 3 2003 279 289
32. K. Kurozumi, T. Tamiya, Y. Ono, S. Otsuka, H. Kambara, and Y. Adachi Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus J. Neurooncol. 66 1-2 2003 117 127
33. C. Fuerer, and R. Iggo 5-Fluorocytosine increases the toxicity of Wnt-targeting replicating adenoviruses that express cytosine deaminase as a late gene Gene Ther. 1 2 2004 142 151
34. A. Muyombwe, M. Olivier, P. Harvie, M.G. Bergeron, M. Ouellette, and B. Papadopoulou Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene J. Infect. Dis. 177 1 1998 188 195
35. H. Corban-Wilhelm, G. Becker, U. Bauder-Wust, D. Greulich, and J. Debus Cytosine deaminase versus thymidine kinase: a comparison of the antitumor activity Clin. Exp. Med. 3 2003 150 156